01—Abstract
Summary
Summary of the 8-K filed February 4, 2025. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2024 results on February 4, 2025, furnished as Exhibit 99.1 to this Item 2.02 Form 8-K.
For the quarter ended December 31, 2024, net sales rose to $862.9 milliona from $788.9 million, with orders of $816.8 million and organic sales up 3%. Reported diluted EPS was $1.62 versus $1.43, and adjusted diluted EPS was $2.04 versus $1.83. Operating cash flow fell to $172.6 million from $201.0 million, and free cash flow declined to $157.1 million from $179.4 million.
Management attributed the sales increase largely to acquisitions, including Mott Corporation, and strong price capture. For full year 2024, net sales were $3,268.8 millionb, roughly flat with $3,273.9 million in 2023, and organic sales declined 2%. Net income attributable to IDEX fell to $505.0 million from $596.1 million, and reported diluted EPS was $6.64 versus $7.85.
Adjusted diluted EPS was $7.89c versus $8.22. Operating cash flow was $668.1 million and free cash flow was $603.0 million, with free cash flow conversion of 101%. Health & Science Technologies saw softness in organic sales, while Fire & Safety/Diversified Products grew organically.
For 2025, IDEX projected full-year organic sales growth of 1% to 3%, GAAP diluted EPS of $6.56 to $6.96d, and adjusted diluted EPS of $8.10 to $8.45. First-quarter 2025 organic sales are projected to decline 3% to 4%, with GAAP diluted EPS of $1.18 to $1.24. Management cited geopolitical and economic uncertainty and reiterated a path toward double-digit earnings expansion.
02—Key points
Key Highlights
- Q4 2024 net sales of $862.9 million, up from $788.9 million, with organic sales up 3% and orders of $816.8 million versus $753.9 million
- Q4 2024 reported diluted EPS of $1.62 versus $1.43; adjusted diluted EPS of $2.04 versus $1.83
- Full year 2024 net sales of $3,268.8 million, essentially flat versus $3,273.9 million, with organic sales down 2%
- Full year 2024 reported diluted EPS of $6.64 versus $7.85; adjusted diluted EPS of $7.89 versus $8.22
- Full year 2024 operating cash flow of $668.1 million and free cash flow of $603.0 million, with free cash flow conversion of 101%
- 2025 guidance: organic sales growth of 1% to 3%, GAAP diluted EPS of $6.56 to $6.96, adjusted diluted EPS of $8.10 to $8.45
- Q1 2025 guidance: organic sales projected to decline 3% to 4%, with GAAP diluted EPS of $1.18 to $1.24
03—Questions
Frequently Asked Questions
What drove the increase in fourth-quarter net sales?
The filing states that net sales increased largely due to the net impact of acquisitions and divestitures, as newly acquired Mott Corporation delivered a major project, and strong price capture was realized across all segments.
Why did operating cash flow decline in the fourth quarter and full year?
For the quarter, operating cash flow decreased to $172.6 million from $201.0 million because higher earnings were more than offset by the timing of customer deposits and project deliveries and the timing of inventory purchase payments. For the full year, lower earnings, timing of customer deposits and project deliveries, and larger prior-year inventory reductions contributed, partly offset by lower cash payments for taxes, variable compensation and interest.
What is IDEX's outlook for 2025?
IDEX projects full-year 2025 organic sales growth of 1% to 3%, GAAP diluted EPS of $6.56 to $6.96, and adjusted diluted EPS of $8.10 to $8.45. For the first quarter, it projects organic sales to decrease 3% to 4% and GAAP diluted EPS of $1.18 to $1.24.
Why did full-year net income attributable to IDEX decline?
The filing attributes the decline in diluted EPS to lower operating results and higher depreciation expense. GAAP diluted EPS also reflects higher amortization expense and the absence of the gain on sale of Micropump, Inc. recorded in the prior year. Net income attributable to IDEX fell to $505.0 million from $596.1 million.
How did the segments perform in the fourth quarter?
Fluid & Metering Technologies net sales were $299.3 million, roughly flat, with 3% organic growth. Health & Science Technologies net sales rose to $373.2 million from $312.7 million, driven by the Mott acquisition, with flat organic sales. Fire & Safety/Diversified Products net sales rose to $192.9 million from $179.0 million, up 8% organically.
04—Continue